Molecular and structural basis of pan-resistance to BTK targeting therapies via BTK A428D mutation By webmaster / December 6, 2025
NX-1607: Translational Insights From a First-in-Human Study of an Oral CBL-B Inhibitor in Advanced Solid Tumors By AldenMC Production / November 7, 2025
A Phase 1 Trial of Zelebrudomide (NX-2127), a First-in-Class BTK Dual-Targeted Protein Degrader, in Patients with Relapsed/Refractory B-cell Malignancies By webmaster / September 5, 2025
Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton’s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies By dev@sirosolutions.com / December 17, 2024
Kinase Impaired BTK Mutations Are Susceptible to Clinical Stage BTK and IKZF1/3 Degrader NX-2127 By dev@sirosolutions.com / December 17, 2024
A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton’s Tyrosine Kinase Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B-Cell Malignancies By dev@sirosolutions.com / December 17, 2024
